• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Infectivity Assay for Detection of SARS-CoV-2 in Samples from Patients with COVID-19

tetano

Editor, Senior Moderator
J Med Virol


. 2021 Jun 17.
doi: 10.1002/jmv.27145. Online ahead of print.
Infectivity Assay for Detection of SARS-CoV-2 in Samples from Patients with COVID-19


Satoshi Hiroi[SUP] 1 [/SUP], Ritsuko Kubota-Koketsu[SUP] 2 [/SUP], Tadahiro Sasaki[SUP] 2 [/SUP], Saeko Morikawa[SUP] 1 [/SUP], Kazushi Motomura[SUP] 1 [/SUP], Emi E Nakayama[SUP] 2 [/SUP], Yoshinobu Okuno[SUP] 3 [/SUP], Tatsuo Shioda[SUP] 2 [/SUP]



Affiliations

Abstract

Since the COVID-19 outbreak, laboratory diagnosis has mainly been conducted using RT-PCR. Detecting the presence of an infectious virus in the collected sample is essential to analyze if a person can transmit it. However, there have been no quantitative investigations conducted for infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in clinical samples. Therefore, in the present study, a rapid and simple focus-forming assay using the peroxidase-antiperoxidase technique was developed to quantify infectious SARS-CoV-2 titers in 119 samples (n = 52, nasopharyngeal swabs [NPS]; n = 67, saliva) from patients with COVID-19. Further, the study findings were compared with the cycle threshold (Ct) values of real-time RT-PCR. The infectious virus titers in NPS samples and Ct values were inversely correlated, and no infectious virus could be detected when the Ct value exceeded 30. In contrast, a low correlation was observed between the infectious virus titers in saliva and Ct values. Further, the infectious virus titers in the saliva were significantly lower than that in the NPS samples. Ten days after the onset of COVID-19 symptoms, the infectious virus was undetectable, and Ct values were >30. The results indicate that patients whose symptoms subsided 10 days after onset, with Ct values >30, were less likely to infect others. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; Ct value; SARS-CoV-2; infectious virus titer; nasopharyngeal swab; saliva.
 
Back
Top Bottom